Substitution of calcineurin inhibitors with sirolimus on left ventricular hypertrophy (LVH) of renal transplant recipients (RTR)

ISRCTN ISRCTN54216890
DOI https://doi.org/10.1186/ISRCTN54216890
Secondary identifying numbers N/A
Submission date
28/04/2008
Registration date
12/05/2008
Last edited
25/02/2013
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Injury, Occupational Diseases, Poisoning
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Not provided at time of registration

Contact information

Dr Giuseppe Cannella
Scientific

L.go R.Benzi 10
Genova
16132
Italy

Study information

Study designNon-randomised controlled trial.
Primary study designInterventional
Secondary study designNon randomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study hypothesisSubstitution of calcineurin inhibitors (CNI) with sirolimus may regress left ventricular hypertrophy (LVH) of renal transplant recipients (RTR).
Ethics approval(s)Ethics approval was not required as this trial complies with the recommendations issued by the ethical committee of the San Martino University Hospital (Azienda Ospedaliera Universitaria San Martino).
ConditionChronic allograft nephropathy in renal transplant recipients; left ventricular hypertrophy
Intervention28 men and 14 women (total of 42 patients) were enrolled in this study.

All patients started CNI therapy. Subjects with chronic allograft nephropathy were switched to sirolimus, whereas patients not having chronic allograft nephropathy continued CNI and served as controls (non-randomised trial). The dose of sirolimus was titrated every other week in order to maintain trough levels between 5 and 15 mg/ml.

Duration of interventions: Interventions will continue as long as the participants require these immunosuppressants.

Total duration of follow-up: 12 months
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)calcineurin inhibitors, sirolimus
Primary outcome measureChanges in left ventricular mass (LVMi) at 12 months
Secondary outcome measuresChanges in serum creatinine as a measure of graft function at 12 months
Overall study start date01/06/2004
Overall study end date31/01/2006

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants42
Participant inclusion criteria1. Age 25-66 years, both males and females
2. Non diabetic RTR with biopsy-proven chronic allograft nephropathy
3. Patients who have received a single kidney in 2004
Participant exclusion criteria1. Diabetic RTR
2. Patients receiving kidney transplant from living donors
3. Patients receiving dual kidney allograft
Recruitment start date01/06/2004
Recruitment end date31/01/2006

Locations

Countries of recruitment

  • Italy

Study participating centre

L.go R.Benzi 10
Genova
16132
Italy

Sponsor information

San Martino University Hospital (Azienda Ospedaliera Universitaria San Martino) (Italy)
University/education

c/o Dr Giuseppe Cannella
L. go R. Benzi 10
Genova
16132
Italy

ROR logo "ROR" https://ror.org/04d7es448

Funders

Funder type

Government

The Italian National Health Service (Servizio Sanitario Nazionale [SSN]) (Italy)

No information available

San Martino University Hospital (Azienda Ospedaliera Universitaria San Martino) (Italy)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/09/2012 Yes No